



FOR IMMEDIATE RELEASE

**THE CENTER FOR GYNECOLOGIC ONCOLOGY CONDUCTING CLINICAL  
RESEARCH STUDY FOR WOMEN WITH RECURRENT OVARIAN CANCER**  
*There Are More Than 225,000 New Cases of Ovarian Cancer Worldwide Each  
Year<sup>1</sup>*

HOLLYWOOD, FL., DATE – The Center for Gynecologic Oncology announced today it is actively enrolling women with recurrent ovarian cancer for participation in a new clinical research study, called TRINOVA-1. Although there have been many significant treatment advances in recent years, 70 to 90 percent of women treated for ovarian cancer ultimately experience a relapse of their disease and many will eventually succumb to the disease.

“For women undergoing a relapse, the way forward is sometimes uncertain,” said Jacob Tangir, M.D., principal investigator for the study at The Center for Gynecologic Oncology. “We are pleased to offer women the opportunity to participate in the TRINOVA-1 trial. There’s more we need to learn about recurrent ovarian cancer and through this trial we ultimately hope to gain a better understanding of potential treatment options for women affected by this disease.”

It is estimated that 21,880 women in the United States will be diagnosed with and 13,850 women will die of ovarian cancer in 2010.<sup>2</sup>

The purpose of the TRINOVA-1 trial is to find out whether adding the investigational drug, AMG 386, to paclitaxel chemotherapy improves the length of time until disease progresses compared to treatment with paclitaxel chemotherapy alone.

## **DRAFT: 20090508 STUDY PRESS RELEASE FOR STUDY SITE APPROVAL**

AMG 386, developed by biotechnology company Amgen, is a product known as an angiogenesis inhibitor. Angiogenesis refers to the body's normal process of creating new blood vessels in order to grow and heal. Cancer cells also require new blood vessels supplying oxygen and nutrients in order for tumors to grow beyond a certain size. Angiogenesis inhibitors are designed to stop the development of these vessels, starving the cancer and slowing down or preventing its growth.

Participants in the study will receive treatment with either paclitaxel chemotherapy plus AMG 386 or paclitaxel chemotherapy alone. The study is open to women 18 years of age or older who have been diagnosed with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, have undergone surgery to remove at least one ovary, and had one prior platinum-based chemotherapy regimen for management of their disease.

Taking part in a clinical research study is voluntary and a personal decision that should be made after speaking with your doctor. For more information, call Gisela Pereira, RN, of The Center for Gynecologic Oncology at (954) 602-9723 or visit [www.TRINOVA-1.com](http://www.TRINOVA-1.com).

###

Media Contact: Caitlin Meaney, Hill & Knowlton, (212) 885-0607

---

<sup>1</sup> Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Lyon, France: International Agency for Research on Cancer; 2010. Available at: <http://globocan.iarc.fr>

<sup>2</sup> American Cancer Society. Available at: <http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-key-statistics> Accessed November 1, 2010.